J&J: Janssen submits application for MS drug in Europe
(CercleFinance.com) - Johnson & Johnson's Janssen said that it has submitted an application for marketing its multiple sclerosis drug Ponesimod in Europe.
Janssen announced the submission of a marketing authorisation application to the European Medicines Agency (EMA), seeking approval for the treatment of adult patients with relapsing multiple sclerosis, the J&J unit said.
Over 700,000 live with multiple sclerosis in Europe, with approximately 85% of them initially diagnosed with the relapsing form of the disease.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Janssen announced the submission of a marketing authorisation application to the European Medicines Agency (EMA), seeking approval for the treatment of adult patients with relapsing multiple sclerosis, the J&J unit said.
Over 700,000 live with multiple sclerosis in Europe, with approximately 85% of them initially diagnosed with the relapsing form of the disease.
Copyright (c) 2020 CercleFinance.com. All rights reserved.